> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Cannabidiol NDA
- URL: https://www.fdaweb.com/panel-to-review-cannabidiol-nda/
- Published: 2018-02-22T12:00:00.000Z
- Updated: 2026-09-14T23:24:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140827

*Federal Register* notice: FDA has announced a 4/19 Peripheral and Central Nervous System Drugs Advisory Committee meeting. Panel members are scheduled to discuss a GW Pharmaceuticals NDA for its cannabidiol oral solution, indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-02-22/pdf/2018-03603.pdf?ref=fdaweb.com).